Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study

Int J Dermatol. 2023 Jul;62(7):888-894. doi: 10.1111/ijd.16717. Epub 2023 May 22.

Abstract

Background: Facial erythema in rosacea is a troublesome embarrassing presentation with limited options of treatment. Daily brimonidine gel was shown to be an effective modality of treatment. Being unavailable in Egypt and the scarcity of objective evaluation of its therapeutic effect motivated the search for other alternatives.

Objective: To evaluate the use and effectiveness of topical brimonidine eye drops for the management of facial erythema in rosacea with the aid of objective assessment.

Methods: The study was conducted on 10 rosacea patients presented with facial erythema. Brimonidine tartrate eye drops 0.2% were applied twice daily for 3 months on areas of red facial skin. Punch biopsies were obtained before and after 3 months of treatment. Routine hematoxylin and eosin (H&E) staining as well as CD34 immunohistochemical staining were performed for all biopsies. Sections were examined to detect the changes in the count and the surface area of blood vessels.

Results: Evaluation of clinical results showed good improvement of facial redness at the end of treatment (55-75%). Only 10% of subjects expressed rebound erythema. H&E and CD34 stained sections showed an increased count of dilated dermal blood vessels, which decreased significantly after treatment in count and surface area (P = 0.005, and P = 0.004, respectively).

Conclusion: Topical brimonidine eye drops proved to be effective in managing facial erythema in rosacea, providing an available and cheaper alternative to brimonidine gel. The study improved the subjective evaluation in the context of objective assessment of treatment efficacy.

MeSH terms

  • Administration, Cutaneous
  • Brimonidine Tartrate / therapeutic use
  • Erythema* / drug therapy
  • Humans
  • Ophthalmic Solutions
  • Rosacea* / drug therapy
  • Treatment Outcome

Substances

  • Brimonidine Tartrate
  • Ophthalmic Solutions